VistaGen Therapeutics Inc./$VTGN
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Ticker
$VTGN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
57
ISIN
US92840H4002
Website
VTGN Metrics
BasicAdvanced
$58M
-
-$1.67
0.69
-
Price and volume
Market cap
$58M
Beta
0.69
52-week high
$2.96
52-week low
$1.90
Average daily volume
168K
Financial strength
Current ratio
6.508
Quick ratio
6.381
Long term debt to equity
1.347
Total debt to equity
2.144
Profitability
EBITDA (TTM)
-55.823
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-10,579.84%
Operating margin (TTM)
-11,517.08%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-33.64%
Return on equity (TTM)
-55.68%
Valuation
Price to revenue (TTM)
127.073
Price to book
0.82
Price to tangible book (TTM)
0.82
Price to free cash flow (TTM)
-1.46
Free cash flow yield (TTM)
-68.48%
Free cash flow per share (TTM)
-136.96%
Growth
Revenue change (TTM)
-54.32%
Earnings per share change (TTM)
9.77%
3-year revenue growth (CAGR)
-24.04%
3-year earnings per share growth (CAGR)
-39.12%
10-year earnings per share growth (CAGR)
-40.86%
VTGN News
AllArticlesVideos
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
Business Wire·1 week ago
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
Business Wire·2 weeks ago
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for VistaGen Therapeutics Inc. stock?
VistaGen Therapeutics Inc. (VTGN) has a market cap of $58M as of July 04, 2025.
What is the P/E ratio for VistaGen Therapeutics Inc. stock?
The price to earnings (P/E) ratio for VistaGen Therapeutics Inc. (VTGN) stock is 0 as of July 04, 2025.
Does VistaGen Therapeutics Inc. stock pay dividends?
No, VistaGen Therapeutics Inc. (VTGN) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next VistaGen Therapeutics Inc. dividend payment date?
VistaGen Therapeutics Inc. (VTGN) stock does not pay dividends to its shareholders.
What is the beta indicator for VistaGen Therapeutics Inc.?
VistaGen Therapeutics Inc. (VTGN) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.